With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy, with continued benefit observed in open-label extension study ...
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance...
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on...
5 Must-Read Analyst Questions From Pfizer’s Q1 Earnings Call
U.S. health officials recently explored whether certain selective serotonin reuptake inhibitors, or SSRIs, could face restrictions as Health Secretary Robert F. Kennedy Jr. prepared a broader initiative...
The spring of 2026 arrived with a vibrant bloom of flowers and an unprecedented, crawling wave of arachnids. Recent social media feeds resemble scenes from a horror movie, a shared experience for millions...
PFE Q1 Deep Dive: Oncology, Obesity Pipeline, and Legal Milestones Shape Outlook
Equities in Toronto edged higher on Tuesday, supported by gains in mining stocks. But advances were ...